What is the primary indication for the medication Epclusa?

Epclusa is primarily indicated for the treatment of hepatitis C, a viral infection that affects the liver. It combines two direct-acting antiviral agents: sofosbuvir and velpatasvir, which work synergistically to inhibit different stages of the hepatitis C virus life cycle. This combination therapy is essential because it provides a pan-genotypic treatment option, meaning it is effective against multiple strains of the virus.

The focus on hepatitis C is crucial as this virus can lead to severe liver diseases, including cirrhosis and liver cancer. Successful treatment with Epclusa can lead to a sustained virologic response, which significantly reduces the risk of liver-related complications and improves overall health outcomes for patients affected by hepatitis C.